NervGen Pharma Corp. announced the formation of its Spinal Cord Injury (SCI) Clinical Advisory Board comprised of five world-class scientific and clinical researchers in the field of spinal cord injury: Drs. James Guest, Steven Kirshblum, Brian Kwon, Linda Jones and Daniel Lammertse. This Clinical Advisory Board will work closely with NervGen as the Company prepares for its upcoming Phase 1b/2 clinical trial for spinal cord injury with its lead compound, NVG-291. James Guest, MD, PhD, FACS, is Professor of Neurological Surgery at the University of Miami and The Miami Project to Cure Paralysis. He is the co-Chair of the North American Clinical Trials Network for spinal cord injury. Steven Kirshblum, MD, is Professor and Chair of the Department of Physical Medicine and Rehabilitation at Rutgers New Jersey Medical School and the Chief Medical Officer for Kessler Institute for Rehabilitation (KIR) and Kessler Foundation (KF). He also serves as the Director of the Spinal Cord Program for KIR, the co-director of the Northern NJ Spinal Cord Injury Model Systems and co-director for the Center for Spinal Stimulation at KF. Dr. Kirshblum has served in many leadership roles for numerous national organizations including past president of Academy of Spinal Cord Professionals, American Paraplegia Society, as well as a current American Spinal Injury Association Board member. Brian Kwon, MD, PhD, FRCSC, is a Professor in the Department of Orthopaedics at the University of British Columbia, the Canada Research Chair in Spinal Cord Injury, and holds the Dvorak Chair in Spine Trauma. Linda Jones, PT, PhD, serves as a consultant to biotechnology companies, universities, and non- profit organizations to advance spinal cord injury research and is a collaborating faculty member at Thomas Jefferson University. Daniel Lammertse, MD, is a Clinical Professor of PM&R at the University of Colorado School of Medicine and is an Emeritus Clinical Scientist at Craig Hospital in Englewood Colorado.